OBJECTIVES: To review outcomes after curative treatment for @entity418 in the Vancouver Island Cancer Centre from 1993 to 1998. Curative treatments included esophagectomy alone, and chemoradiotherapy with "selective surgery" for @entity1 with post-treatment-positive endoscopic biopsy or less than 75% regression on computed axial tomography scan, or with resectable local recurrence. METHODS: @entity1 undergoing esophagectomy alone, or primary chemoradiotherapy and "selective surgery" were reviewed. This was a retrospective, nonrandomized, institutional experience. @entity532 , relief of @entity1282 , disease-specific survival rates and prognostic factors were analyzed. RESULTS: Nineteen @entity1 underwent esophagectomy alone. A total of 56 @entity1 underwent primary chemoradiotherapy, of whom 16 had "selective surgery". Relief of @entity1282 was similar in both groups of esophagectomy @entity1 . Exploration for "selective surgery" was performed in 12 @entity1 after their first postchemo-radiotherapy endoscopy (two @entity1 had unresectable disease), and in seven for relapse, one of whom died intraoperatively. Overall, the mortality rate due to surgery was 3%. Chemoradiotherapy was not associated with more frequent serious surgical complications. For @entity1 who underwent esophagectomy alone and those who underwent chemoradiotherapy plus selective surgery, the median survival times were 12.9 and 16.4 months, respectively, and the three-year survival rates were 21% and 37%, respectively. Seventeen of 25 @entity1 who underwent chemoradiotherapy and who survived more than two years have not required selective surgery. For the two groups of @entity1 combined, no single prognostic factor for survival was significant in multivariate analysis, but for @entity1 who underwent chemoradiotherapy plus selective surgery, negative endoscopic biopsy was highly significant. CONCLUSIONS: @entity532 and disease-specific survival rates after primary chemoradiotherapy with selective surgery compare favourably with esophagectomy alone in the curative treatment of @entity418 . A prospective, randomized trial is necessary for the definitive evaluation of the strategy of chemoradiotherapy and selective surgery.

Curative treatment for XXXX : Vancouver Island Cancer Centre experience from 1993 to 1998.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity532 :: ('MESH:D003925', 'Disease') :: ['Surgical complication'] @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer'] @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']
@entity418 :: (MESH:D004938,Disease) :: ['esophageal cancer']
